{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-268404","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.032759+00:00","generated_at":"2026-05-29T11:23:27.637836+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo","bullets":["NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).","PDAC 2L: ORR 36% (G12X) and 27% (broader RAS); median PFS 8.8 and 8.5 mo; 6-mo OS 100% and 97% (cutoff Jul 23, 2024).","PDAC safety at 300 mg: 34% Grade ≥3 TRAEs, no Grade 5; median duration 5.2 mo, mean dose intensity 89%.","NSCLC safety: Grade ≥3 TRAEs 27% overall, 41% at 300 mg; one Grade 4 pneumonitis at 300 mg; median duration 5.5 mo (120-220 mg).","Combination RMC-6236+RMC-6291 in KRAS G12Ci-experienced CRC: ORR 25% (3/12), DCR 92%; plans for Phase 3 NSCLC trial vs docetaxel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-268404","json":"https://secwatch.observer/filing/0001193125-24-268404.json","markdown":"https://secwatch.observer/filing/0001193125-24-268404.md","text":"https://secwatch.observer/filing/0001193125-24-268404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/0001193125-24-268404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524268404/d169582d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:23:27.637836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}